{
    "clinical_study": {
        "@rank": "43598", 
        "arm_group": {
            "arm_group_label": "Icotinib Hydrochloride", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days."
        }, 
        "brief_summary": {
            "textblock": "This phase \u2161 study was designed to evaluate the efficacy and safety of Icotinib\n      Hydrochloride as treatment for patients with recurrent or metastasis esophageal squamous\n      carcinoma after failure of conventional chemotherapy. Prospective evaluation of biomarkers\n      is also performed in searching for appropriate  predictive  molecular markers of benefit\n      people treated with Icotinib Hydrochloride as second-line theory in esophageal squamous\n      carcinoma."
        }, 
        "brief_title": "Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Cancer After Failure of Conventional Chemotherapy", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Esophageal Squamous Cell Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Esophageal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "Currently, there is no standard second-line therapy for esophageal squamous cell carcinoma.\n      More effective therapy for patients with this disease who developed disease progression\n      after first line therapy is needed. Although Erlotinib is recommended in NCCN Guideline\n      Version 2.2013, there is still insufficient evidence on EGFR-TKI as second-line therapy for\n      esophageal squamous carcinoma. Therefore,further research is necessary.In this phase \u2161\n      study, we evaluate the efficacy and safety of Icotinib Hydrochloride as treatment for\n      patients with recurrent or metastasis esophageal squamous carcinoma after failure of\n      conventional chemotherapy\uff0cand analyse the value of biomarkers of these patient to identify\n      who benefit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients have provided a signed Informed Consent Form\n\n          -  Age: 18-75 years old\n\n          -  Histologically confirmed diagnosis of esophageal squamous cell carcinoma\n\n          -  Patients have Received and progressed on 1 line of prior Fluoropyrimidine, platinum\n             or taxane based palliative chemotherapy\n\n          -  Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1\n             criteria\n\n          -  Life expectancy \u2265 3 months\n\n          -  Karnofsky score \u226570\n\n          -  Patient has adequate bone marrow and organ function\n\n               -  Absolute Neutrophil Count (ANC) \u2265 1.5 x 109/L\n\n               -  Platelets \u2265 75 x 109/L\n\n               -  Hemoglobin \u2265 9.0 g/dL\n\n          -  Patient has adequate liver function\n\n               -  AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is\n                  liver metastasis)\n\n               -  Serum bilirubin \u2264 2 x ULN\n\n          -  Creatinine \u2264 1.5 times ULN\n\n          -  No malabsorption or other gastrointestinal disorders affecting drug absorption.\n\n          -  No serious complications such as active gastrointestinal hemorrhage, perforation,\n             jaundice, gastrointestinal obstruction, non cancerous fever > 38 \u2103.\n\n          -  Expect good compliance\n\n        Exclusion Criteria:\n\n          -  Patient has received previous treatment with EGFR inhibitors\n\n          -  Patient is currently receiving Phenytoin, rifampin, barbiturates, C Masi Bing\n\n          -  Known severe hypersensitivity to Icotinib or any of the excipients of this product\n\n          -  CNS metastases without radiotherapy and/or surgery\n\n          -  Patients with treated CNS metastases may participate in this trial,except for those\n             who must receive hormone therapy and those whose prior hormone therapy for CNS\n             metastases is less than 4 weeks\n\n          -  Evidence of clinically active Interstitial Lung Diseases\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases\n\n          -  Patient has a concurrent malignancy or has a malignancy within 5 years of study\n             enrollment, (with the exception of nonmelanoma skin cancer or cervical carcinoma in\n             situ\n\n          -  psychiatric illness that would prevent the patient from giving informed consent\n\n          -  Patient is concurrently using other approved or investigational antineoplastic agent\n\n          -  Pregnant or lactating women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01973725", 
            "org_study_id": "ICO-29"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib Hydrochloride", 
            "description": "Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.", 
            "intervention_name": "Icotinib Hydrochloride", 
            "intervention_type": "Drug", 
            "other_name": "Conmana"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 15, 2014", 
        "location": {
            "contact": {
                "email": "liyh@sysucc.org.cn", 
                "last_name": "Li Yuhong, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Guangzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }, 
            "investigator": {
                "last_name": "Li Yuhong, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase\u2161 Study of Icotinib Hydrochloride in Treating Patients With Recurrent or Metastatic Esophageal Squamous Carcinoma After Failure of Conventional Chemotherapy", 
        "overall_contact": {
            "email": "liyh@sysucc.org.cn", 
            "last_name": "Li Yuhong, MD"
        }, 
        "overall_official": {
            "affiliation": "Sun Yat-sen University", 
            "last_name": "Li Yuhong, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Disease control rate", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01973725"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Yuhong Li", 
            "investigator_title": "MD", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "Time from day 1 to date of death"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "Time from day 1 to date of documented disease progression"
            }, 
            {
                "description": "Safety data will be assessed at each study visit using NCI CTCAE version 3.0", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "Each follow up vist, assessed up to 12 months"
            }, 
            {
                "description": "Quality of life will be assessed at each study visit using EORTC QLQ-C30 and QLQ-OES18", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "Time from day 1 to date of death"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhong Li", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}